Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt
Agitated Solutions, Inc. · with Bright Research Partners · NCT06938347
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 3
- Target enrollment
- 300
- US sites recruiting
- 7
- Study start
- November 5, 2025
- Record last updated
- July 6, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is a phase 3, multicenter, open-label, blinded, crossover trial in which each participant will undergo a randomized sequence of ASI-02 and agitated saline standard of care (SoC) via a saline contrast transthoracic echocardiogram (TTE) study.
Being studied: Agitated Saline SoC; ASI-02
Conditions: Right-To-Left Shunt
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Patient is clinically indicated for a saline contrast TTE study with a suspected right-to-left shunt
- Patient must be at least 18 years of age inclusive, at the time of signing the informed consent
- Able to communicate effectively with trial personnel
Exclusion Criteria
- Female patients who are pregnant or lactating. All women of child-bearing potential (WOCBP) must have a negative urine pregnancy test at screening regardless of contraceptive use history
- WOCBP are excluded unless they have been using an adequate and medically approved method of contraception to avoid pregnancy for at least 1 month prior to ASI-02 dose administration
- Allergy to polysorbate 80 (PS-80)
- American Society of Anesthesiologists (ASA) physical status classification IV, V, or VI, except that participants with ASA physical status IV due solely to recent suspected transient ischemic attack or cerebrovascular accident are eligible for inclusion
- Current illness or pathology that in the opinion of the investigator would prevent undergoing investigational product administration due to a significant safety risk to the patient
- Uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 200 mmHg or diastolic blood pressure ≥ 110 mmHg) or arterial hypotension (defined as systolic blood pressure ≤ 90 mmHg)
- Unstable cardiovascular status defined as:
- myocardial infarction or unstable angina pectoris within 6 months prior to procedure day
- symptomatic valvular heart disease or moderate to severe stenotic valvular heart disease
- clinically significant congenital heart defects (excluding an atrial septal defect [ASD], patent foramen ovale [PFO], or pulmonary arteriovenous malformation [PAVM])
- current uncontrolled cardiac arrhythmias causing clinical symptoms requiring medical intervention or hemodynamic compromise
- acute pulmonary embolus or pulmonary infarction
- acute myocarditis or pericarditis
- acute aortic dissection
- untreated atrial fibrillation
- Any major surgery within 30 days prior to screening
- Participation in any investigational drug, device, or placebo study within 30 days prior to screening
- Vulnerable adult participant populations (e.g., incarcerated or cognitively challenged adults)
Recruiting US locations
Northwestern University
Chicago, IL 60611
Site contact: Akhil Narang, MD
AH Illinois Masonic Center
Chicago, IL 60657
Site contact: Sorin Danciu, MD
Mayo Clinic
Rochester, MN 55905
Site contact: Sunil Mankad, MD
CentraCare
Saint Cloud, MN 56303
Site contact: Timothy Schuchard, MD
Jackson Heart Clinic
Jackson, MS 39216
Site contact: William Crowder, MD
NYU Langone Health
New York, NY 10016
Site contact: Daniel Bamira, MD
Aurora St. Lukes Medical Center
Milwaukee, WI 53215
Site contact: Renuka Jain, MD
Study contacts (from the official record)
- Pamela Wolfe · 763-258-7027 · pamela@agitatedsolutions.com
- Rebecca Zickert · 612-345-4544 · rebecca.zickert@brightresearch.com